EGFR and metastatic colorectal cancer: The authors identified three drug-response clusters within the metastatic colorectal cancer groups; this was based on sensitivities to epidermal growth factor receptor (EGFR) and/or murine double minute 2 (MDM2) inhibition, and correlating with RAS mutations as well as TP53 activity.